Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › HDM1702 vs Wegovy (bioequivalence)

HDM1702 vs Wegovy (bioequivalence)

HDM1702 · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HDM1702
Population
obesity
Phase
3
Participants
462
Duration
44 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
HDM1702 2.4 mg vs semaglutide (Wegovy): −16.27 %obesity china44462—−15.2 %———————congress

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HDM1702 vs Wegovy (bioequivalence). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1702-vs-wegovy/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.